Literature DB >> 19739237

Centrosomes and myeloma; aneuploidy and proliferation.

Wee J Chng1, Rafael Fonseca.   

Abstract

Multiple myeloma is the second most common hematological malignancy in the United States. The disease is characterized by an accumulation of clonal plasma cells. Clinically, patients present with anemia, lytic bone lesions, hypercalcaemia, or renal impairment. The genome of the malignant plasma cells is extremely unstable and is typically aneuploid and characterized by a complex combination of structure and numerical abnormalities. The basis of the genomic instability underlying myeloma is unclear. In this regard, centrosome amplification is present in about a third of myeloma and may represent a mechanism leading to genomic instability in myeloma. Centrosome amplification is associated with high-risk features and poor prognosis. Understanding the underlying etiology of centrosome amplification in myeloma may lead to new therapeutic avenues. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19739237      PMCID: PMC2760667          DOI: 10.1002/em.20528

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.216


  75 in total

1.  Clinical implication of centrosome amplification in plasma cell neoplasm.

Authors:  Wee J Chng; Greg J Ahmann; Kim Henderson; Rafael Santana-Davila; Philip R Greipp; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John A Lust; Robert A Kyle; Steven R Zeldenrust; Suzanne R Hayman; Rafael Fonseca
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

2.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

3.  Short term cyclin D1 overexpression induces centrosome amplification, mitotic spindle abnormalities, and aneuploidy.

Authors:  Christopher J Nelsen; Ryoko Kuriyama; Betsy Hirsch; Vivian C Negron; Wilma L Lingle; Melissa M Goggin; Michael W Stanley; Jeffrey H Albrecht
Journal:  J Biol Chem       Date:  2004-10-26       Impact factor: 5.157

4.  The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle.

Authors:  S Duensing; L Y Lee; A Duensing; J Basile; S Piboonniyom; S Gonzalez; C P Crum; K Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

5.  Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression.

Authors:  G A Pihan; A Purohit; J Wallace; R Malhotra; L Liotta; S J Doxsey
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

6.  Identification of two hyaluronan-binding domains in the hyaluronan receptor RHAMM.

Authors:  B Yang; L Zhang; E A Turley
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

7.  The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo.

Authors:  Emmy W Verschuren; Juha Klefstrom; Gerard I Evan; Nic Jones
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

8.  Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes.

Authors:  Kai Neben; Björn Tews; Gunnar Wrobel; Meinhard Hahn; Felix Kokocinski; Christian Giesecke; Ulf Krause; Anthony D Ho; Alwin Krämer; Peter Lichter
Journal:  Oncogene       Date:  2004-03-25       Impact factor: 9.867

Review 9.  Mutations and aneuploidy: co-conspirators in cancer?

Authors:  German Pihan; Stephen J Doxsey
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

10.  Genetics and cytogenetics of multiple myeloma: a workshop report.

Authors:  Rafael Fonseca; Bart Barlogie; Regis Bataille; Christian Bastard; P Leif Bergsagel; Marta Chesi; Faith E Davies; Johannes Drach; Philip R Greipp; Ilan R Kirsch; W Michael Kuehl; Jesus M Hernandez; Stephane Minvielle; Linda M Pilarski; John D Shaughnessy; A Keith Stewart; Herve Avet-Loiseau
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

View more
  9 in total

Review 1.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

Review 2.  Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.

Authors:  Adriana Zingone; W Michael Kuehl
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

3.  Gene expression profiling and in vitro functional studies reveal RAD54L as a potential therapeutic target in multiple myeloma.

Authors:  Ivyna Pau Ni Bong; Ching Ching Ng; Norodiyah Othman; Ezalia Esa
Journal:  Genes Genomics       Date:  2022-06-11       Impact factor: 2.164

Review 4.  A clinical overview of centrosome amplification in human cancers.

Authors:  Jason Yongsheng Chan
Journal:  Int J Biol Sci       Date:  2011-10-16       Impact factor: 6.580

5.  Deficient spindle assembly checkpoint in multiple myeloma.

Authors:  Elena Díaz-Rodríguez; Stela Álvarez-Fernández; Xi Chen; Bruno Paiva; Ricardo López-Pérez; Juan Luis García-Hernández; Jesús F San Miguel; Atanasio Pandiella
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

6.  Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability.

Authors:  Ana B Herrero; Jesús San Miguel; Norma C Gutierrez
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

Review 7.  The therapeutic potential of cell cycle targeting in multiple myeloma.

Authors:  Anke Maes; Eline Menu; Kim De Veirman; Ken Maes; Karin Vand Erkerken; Elke De Bruyne
Journal:  Oncotarget       Date:  2017-06-28

Review 8.  DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment.

Authors:  Takayuki Saitoh; Tsukasa Oda
Journal:  Cancers (Basel)       Date:  2021-01-28       Impact factor: 6.639

9.  Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.

Authors:  Anna Pagotto; Otavia L Caballero; Norbert Volkmar; Sylvie Devalle; Andrew J G Simpson; Xin Lu; John C Christianson
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.